Cancer cells have a bizarre 'trash disposal' system where they literally spit out their own damaged parts to survive chemotherapy.
April 17, 2026
Original Paper
Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting the PLK1-CEP55-ESCRT Axis to Suppress Nuclear Budding and Mitochondrial-derived Vesicles Extrusion
ChemRxiv · chemrxiv-2024-0gmkw/v2
The Takeaway
When chemotherapy damages a cancer cell, we expect it to die. However, researchers discovered that some cancer cells have a 'holy shit' survival trick: they package their damaged nuclei and mitochondria into tiny bubbles and eject them from the cell. By 'throwing away' the parts of themselves that the chemo hurt, they can keep living and growing. This study identified a compound that blocks this 'extrusion' process, effectively forcing the cancer cell to keep its own trash and die. This reveals a previously unknown way that cancer resists treatment and gives us a brand-new way to stop it in its tracks.
From the abstract
Oxaliplatin (L-OHP) is a first-line chemotherapeutic agent for both advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, the development of acquired L-OHP resistance remains a major clinical obstacle. Here, we identify Tubocapsenolide A (TA), a natural withanolide isolated from Tubocapsicum anomalum, as a potent antitumor agent that not only suppresses CRC growth but also effectively reverses acquired L-OHP resistance. Using a PROTAC-based target deconvolution strategy c